GlaxoSmithKline in Ireland
GSK employs 1,450 people in Ireland and first established operations here in 1975. It has two manufacturing operations in Dungarvan and is the largest employer in the town with almost 700 staff; it has a third manufacturing operation, where it develops and produces a range of bulk pharmaceuticals, together with R&D and European Trading operations in Cork; and in Dublin there are Sales and Marketing functions.
Cork – a strategic global new product introduction site
Established in 1974, the Cork plant is a strategic global new product introduction site within GSK’s manufacturing network and is currently the sole production site for a number of the Group’s top selling drugs such as Seroxat which is an anti-depressant, Avandia which addresses Type 2 diabetes and Coreg which treats serious heart conditions.
€250 million investment in Cork production site
GlaxoSmithKline (GSK) is to invest up to €250 million over five years in its production site at Currabinny, Co. Cork to manufacture products, including the active ingredient for TYKERB® (lapatinib), a new oral treatment for advanced breast cancer. The investment is supported by IDA Ireland and will create up to 150 new high level positions.
Dungarvan – base for two manufacturing plants
GSK has two manufacturing plants based in Dungarvan, Co. Waterford. One is a global pharmaceutical manufacturing facility engaged in the production of a range of over the counter pharmaceuticals. Products include Panadol, Coldrex, Solpadeine and Panadol Extra. The second is an oral care facility manufacturing products such as dental fixative and denture cleaning tablets.
€30 million manufacturing expansion in Dungarvan
GSK has two manufacturing plants in Dungarvan, Co. Waterford. A global pharmaceutical manufacturing facility establish in 1987 engaged in the production of over the counter (OTC) pharmaceuticals and smoking cessation products.
In January 2007, GSK announced an expansion involving €23m investment to increase capacity for the introduction of new Panadol products. A further expansion of its OTC site was announced in April 2008 with the addition of smoking cessation products to Dungarvan’s manufacturing remit. This involves a €30 million investment and 50 new jobs.
An oral care facility manufacturing products such as dental fixative and denture cleaning tablets, established since 1981.